Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)

Trial Profile

ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2019

At a glance

  • Drugs Everolimus (Primary) ; Telaglenastat (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ENTRATA
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 04 Feb 2019 Status changed from recruiting to active, no longer recruiting, according to a Calithera Biosciences media release.
    • 07 Jan 2019 According to a Calithera Biosciences media release, data from this study is expected in H2 2019.
    • 05 Oct 2018 According to a Calithera Biosciences media release, Topline results are expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top